Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience

Benjamin Heyman, Michael Choi, Thomas J. Kipps · 2026

Read Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience by Benjamin Heyman, Michael Choi, Thomas J. Kipps (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13278369.txt.

Description

Benjamin Heyman and colleagues present a 2026 real-world study of drug pairs for a blood cancer that came back or stopped responding to care. The cancer is chronic lymphocytic leukemia. The team reviewed 98 patients treated at UC San Diego from 2012 to 2024. All got venetoclax, a targeted drug, alone or with a second drug.

Paired treatment beat venetoclax alone. Full remission and no detectable leftover disease were most common when the second drug was obinutuzumab. Over a median follow-up of fifty-two months, time without disease growth was longer for paired groups: about seventy-seven months versus about fifty-nine for single-drug care. The results back paired care in daily practice, most of all for high-risk patients.

Catalog record

CREATORBenjamin Heyman, Michael Choi, Thomas J. Kipps
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8017
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13278369

Browse the full library · About the Tower of Babel